Truist Financial Corp Bio Xcel Therapeutics, Inc. Transaction History
Truist Financial Corp
- $62.9 Billion
- Q3 2024
A detailed history of Truist Financial Corp transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Truist Financial Corp holds 10,879 shares of BTAI stock, worth $3,807. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,879
Previous 10,879
-0.0%
Holding current value
$3,807
Previous $13,000
53.85%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding BTAI
# of Institutions
55Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$420,4810.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$154,2390.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$104,3150.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$64,7700.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$45,4540.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $9.81M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...